# TB-500 and Tissue Repair: What the Research Shows

> TB-500 tissue repair: full-length thymosin beta-4 accelerated re-epithelialization 42–61% in rat wounds and improved burn and venous-ulcer healing. The animal record, and the human gap, cited.

The wound, burn, corneal, and ulcer literature — quantified where the studies quantified it, and labelled where the molecule was the full protein rather than the fragment.

## The wound-healing data, quantified

TB-500 tissue repair claims rest, at their strongest, on a single well-characterized animal study. In a rat full-thickness wound model, full-length thymosin beta-4 — topical or intraperitoneal — increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, raised wound contraction by at least 11% by day seven, and increased collagen deposition and angiogenesis [3]. In the same work, as little as 10 pg of thymosin beta-4 stimulated keratinocyte migration two- to three-fold [3].

The magnitudes are worth stating plainly because they are large and they are measured. A 42–61% acceleration of re-epithelialization is a substantial effect for a wound-repair agent. The honest framing is equally plain: this is the parent protein, in rats, by topical and intraperitoneal routes — not the TB-500 heptapeptide, and not a human result. The picogram-level keratinocyte activity is in-vitro.

This is the anchor of the [latest thymosin beta-4 research](/tissue-repair) on repair, and it is the reason wound healing dominates the TB-500 narrative. It is also the reason the identity caveat matters most here: the headline numbers belong to the 4963 Da protein.

## Burn, venous-ulcer, and corneal repair

Beyond the rat wound model, the repair literature widens — and stays, for the most part, on the parent protein. Thymosin beta-4 improved dermal burn-wound healing via downregulation of the receptor for advanced glycation end-products in a db/db mouse model [8]. A European prospective, randomized study reported wound-healing benefit with thymosin beta-4 in venous (pressure/stasis) ulcers — among the earliest human wound-healing observations for the protein [7].

The ophthalmic line is the one with the most human-trial development: clinical-grade topical thymosin beta-4 (RGN-259) has been studied in dry-eye and corneal-healing trials. Extending that work, a 2025 study reported that an engineered tandem thymosin peptide promoted corneal wound healing — a next-generation construct built for greater repair potency [16].

Across these tissues the pattern holds: the protein, or an engineered derivative of it, accelerates repair in animal models and a few topical human studies. The isolated TB-500 fragment is not the molecule in these studies. Where you read 'thymosin beta-4' here, read the parent protein.

## Why the repair signal does not equal a human result

Two facts keep the repair story honest. First, there are zero completed controlled clinical trials of the TB-500 heptapeptide for any indication [6]; the human record is the parent protein's Phase 1 IV safety study and topical ophthalmic trials, neither of which tested the fragment for tissue repair [6]. Second, the preclinical record is not uniformly positive: in dystrophin-deficient mdx mice, chronic thymosin beta-4 increased regenerating fibers but did not improve muscle strength, cardiac function, or fibrosis, and systemic thymosin beta-4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study.

The dose response is also non-monotonic. In the rat embolic-stroke study, 2 and 12 mg/kg improved outcomes but 18 mg/kg did not [4] — higher is not necessarily better, which directly undercuts community 'loading' rationales. The 2026 Sports Medicine review states the boundary for this audience: favorable animal-model repair outcomes, scarce rigorous human safety data, potential for serious harm, and operation largely outside regulatory oversight [11].

So the repair signal is real, reproducible in places, and large in the best wound study — and it is preclinical, mostly on a different molecule than the one sold as TB-500, with no completed fragment trial behind it. The findings and the gap are both on the record.

## Inline questions on tissue repair

These appear inline here and in full on the FAQ index.

---

A fiduciary-grade reading of the TB-500 and thymosin beta-4 record — each finding weighed against its own study and graded for evidence, the fragment-versus-protein line drawn in plain sight, with no clinic, pharmacy, or prescription behind the desk and nothing here dispensed or for sale.